When.com Web Search

  1. Ads

    related to: her 2 negative versus positive

Search results

  1. Results From The WOW.Com Content Network
  2. HER2 - Wikipedia

    en.wikipedia.org/wiki/HER2

    [9] [17] HER2-positive breast cancers are well established as being associated with increased disease recurrence and a poor prognosis compared with other identifiably genetically distinct breast cancers with other known, or lack thereof, genetic markers that are thought to be associated with other breast cancers; however, drug agents targeting ...

  3. Breast cancer classification - Wikipedia

    en.wikipedia.org/wiki/Breast_cancer_classification

    Cells with none of these receptors are called basal-like or triple negative. HER2-low has some HER2 proteins on the cell surface, but not enough to be classified as HER2-positive. [4] Trastuzumab deruxtecan is the first approved therapy by the US Food and Drug Administration (FDA) targeted to people with the HER2-low breast cancer subtype. [4]

  4. Endocrine therapy resistance in breast cancer - Wikipedia

    en.wikipedia.org/wiki/Endocrine_therapy...

    The overexpression of HER2 is determined by immunohistochemistry (IHC), or with fluorescent in situ hybridization in those equivocal cases where IHC does not provide a clear result. Different molecular subtypes of breast cancer have also been described, which loosely align with receptor status: Luminal A (ER and/or PR positive; HER2 negative)

  5. FDA Approves AstraZeneca's Datroway For Pretreated Breast ...

    www.aol.com/finance/fda-approves-astrazenecas...

    On Friday, the U.S. Food and Drug Administration (FDA) approved AstraZeneca Plc’s (NASDAQ:AZN) Datroway (datopotamab deruxtecan or Dato-DXd) for adult patients with unresectable or metastatic ...

  6. Triple-negative breast cancer - Wikipedia

    en.wikipedia.org/wiki/Triple-negative_breast_cancer

    HER2 overexpression positive; triple-negative; There are targeted therapies for estrogen and progesterone receptor cancers and more recently HER2 receptor cancers but there are no targeted therapies for TNBC as a whole. [13] The threshold level for hormone receptor positivity was changed in 2010 and now requires more than 1% positive tumor ...

  7. Buparlisib - Wikipedia

    en.wikipedia.org/wiki/Buparlisib

    Buparlisib was under investigation as a treatment for advanced or metastatic HER2-negative breast cancer in several phase III clinical trials: . The phase III trial BELLE-2 compared buparlisib + fulvestrant with fulvestrant alone in patients with advanced or metastatic HER2-negative, hormone receptor-positive (HR+) aromatase inhibitor-resistant breast cancer.

  1. Ads

    related to: her 2 negative versus positive